Cymbalta Approved; Lilly Antidepressant Will Be Available By Late August
This article was originally published in The Pink Sheet Daily
Executive Summary
Cymbalta (duloxetine) clears FDA for major depressive disorder after a lengthy review. It will be priced comparably to other antidepressants, including Wyeth's Effexor XR (venlafaxine), the other marketed selective serotonin/norepinephrine reuptake inhibitor.
You may also be interested in...
Lilly's Cymbalta Label Adds Postmarketing Data On Hepatotoxicity
Revised labeling for Lilly's Cymbalta extends hepatotoxicity Precaution based on postmarketing reports.
Lilly's Cymbalta Label Adds Postmarketing Data On Hepatotoxicity
Revised labeling for Lilly's Cymbalta extends hepatotoxicity Precaution based on postmarketing reports.
Lilly 2005 Sales Growth Will Rest On Strength Of New Products
Sales of the eight products that Lilly has launched since November 2001 are projected to account for 20% of total sales, CFO Golden tells analysts. Lilly expects Yentreve (duloxetine) to win FDA approval for stress urinary incontinence in the first half of 2005.